Genmab A/S (GMAB) Stock

About Genmab A/S

Genmab A/S, a biopharmaceutical company founded in 1999 and headquartered in Copenhagen, Denmark, specializes in the discovery and development of innovative antibody therapies primarily for treating cancer and various other serious illnesses. The company's commercialized portfolio includes several key products: DARZALEX (daratumumab), a human monoclonal antibody for multiple myeloma (MM), non-MM blood cancers, and AL amyloidosis; teprotumumab, indicated for thyroid eye disease; ofatumumab, another human monoclonal antibody used in chronic lymphocytic leukemia (CLL) and multiple sclerosis; Amivantamab, for advanced or metastatic gastric or esophageal cancer and non-small cell lung cancer (NSCLC); and tisotumab vedotin, which targets cervical, ovarian, and solid tumors. Genmab maintains a robust pipeline of investigational medicines. These include GEN1047; DuoBody-PD-L1x4-1BB and DuoBody-CD40x4-1BB, both developed for solid tumors; Epcoritamab, in development for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and DuoHexaBody-CD37, aimed at hematological malignancies. Furthermore, the company has several products in Phase 2 clinical trials: Teclistamab for vaso-occlusive crises; Camidanlumab tesirine for Hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 for MM; PRV-015 for celiac disease; Mim8 for haemophilia A; and Lu AF82422 for multiple system atrophy disease. In addition to its clinical programs, Genmab is advancing approximately 20 active pre-clinical programs. Genmab fosters strategic collaborations to further its research and development efforts. It holds a commercial license and co-development agreement with Seagen Inc. for tisotumab vedotin. The company also partners with CureVac AG on the research and development of differentiated mRNA-based antibody products and with AbbVie for the development of epcoritamab. Further alliances include BioNTech, Janssen, Novo Nordisk A/S, BliNK Biomedical SAS, and Bolt Biotherapeutics, Inc.

Genmab A/S is headquartered in DK.

Genmab A/S (GMAB) stock trades at $29.00 with a market capitalization of $17.80B. The stock is valued at a price-to-earnings (P/E) ratio of 21.45, price-to-book of 3.09, price-to-sales of 1.86. Over the past 52 weeks the stock has ranged between $21.00 and $35.43, and currently trades 18.1% below its 52-week high.

On profitability, Genmab A/S generates a return on equity (ROE) of 14.53%, return on capital employed of 11.49%, an operating margin of 13.67%, a net profit margin of 8.73%.

In its most recent fiscal year, Genmab A/S reported annual revenue of $3.7B, net profit of $964.0M. Over the last 5 fiscal years, revenue declined at an average annual rate of 18.1%, and net profit declined at an average annual rate of 27.3%.

The balance sheet shows a debt-to-equity ratio of 0.94, a current ratio of 2.18, total assets of $12.8B, $1.7B in cash and equivalents.

GMAB has an average daily trading volume of 1,865,178 shares, a beta of 0.69 (historically less volatile than the overall market).

Official website: www.genmab.com

Genmab A/S by the numbers, 2016–2025

Between 2016 and 2025 Genmab A/S reported revenue of $1.8B rising to $3.7B, a change of +105.0% across 10 years. Compounded, revenue has grown -18.1% a year over five years, -36.5% over three, -82.7% over the last twelve months. Net profit fell to $964.0M.

Operating margin went from 58.0% in 2016 to 33.6% in 2025, a fall of 24.4 percentage points. The most recent net margin is 8.73%. On a trailing twelve-month basis to Mar '26, revenue is $3.9B and net profit $821.0M.

Borrowings stand at $5.4B, cash on hand is $1.5B, cash from operations was $1.2B in the latest year, positive in 10 of the last 10.

Return on equity has averaged 17.0% over five years, and was 16.5% in the most recent year.

The share price itself has compounded at —% a year over five years, -8.4% over three, 32.7% over the last year. Past price movement is history, not a forecast.

Figures are as reported and in the company's own reporting currency. They describe what has already happened and carry no implication about what follows.

Genmab A/S (GMAB) — frequently asked questions